About: Efficacy and safety of umbilical cord mesenchymal stem cells in treatment of cesarean section skin scars: a randomized clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of umbilical cord mesenchymal stem cells in treatment of cesarean section skin scars: a randomized clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Efficacy and safety of umbilical cord mesenchymal stem cells in treatment of cesarean section skin scars: a randomized clinical trial
Creator	Han, Zhongchao Guo, Xiaoling Fan, Dazhi Lin, Dongxin Liu, Zhengping Ma, Huiting Rao, Jiaming Wu, Shuzhen Xia, Qing Ye, Shaoxin Zeng, Meng Zhang, Huishan
source	PMC
abstract	BACKGROUND: Pathological skin scars, caused by cesarean section, affected younger mothers esthetically and psychosocially and to some extent frustrated obstetricians and dermatologists. Umbilical cord mesenchymal stem cells (UC-MSCs), as a population of multipotent cells, are abundant in human tissues, providing several possibilities for their effects on skin scar tissues. Herein, we performed a randomized, double-blind, placebo-controlled, three-arm clinical trial, aiming to assess the efficacy and safety of UC-MSCs in the treatment of cesarean section skin scars among primiparous singleton pregnant women. METHODS: Ninety primiparous singleton pregnant women undergoing elective cesarean section were randomly allocated to receive placebo, low-dose (3 × 10(6) cells), or high-dose (6 × 10(6) cells) transdermal hydrogel UC-MSCs on the surface of the skin incision. The primary outcome was cesarean section skin scars followed after the sixth month, assessed by the Vancouver Scar Scale (VSS). RESULTS: All the participants completed their trial of the primary outcome according to the protocol. The mean score of estimated total VSS was 5.52 in all participants at the sixth-month follow-up, with 6.43 in the placebo group, 5.18 in the low-dose group, and 4.71 in the high-dose group, respectively. No significant difference was found between-group in the mean scores for VSS at the sixth month. Additional prespecified secondary outcomes were not found with significant differences among groups either. No obvious side effects or adverse effects were reported in any of the three arms. CONCLUSION: This randomized clinical trial showed that UC-MSCs did not demonstrate the effects of improvement of cesarean section skin scars. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02772289. Registered on 13 May 2016.
has issue date	2020-06-25(xsd:dateTime)
bibo:doi	10.1186/s13287-020-01695-7
has license	cc-by
sha1sum (hex)	4140dbd5844197838ad213c4b315dfd89e0c0b39
schema:url	https://doi.org/10.1186/s13287-020-01695-7
resource representing a document's title	Efficacy and safety of umbilical cord mesenchymal stem cells in treatment of cesarean section skin scars: a randomized clinical trial
has PubMed Central identifier	PMC7316165
schema:publication	Stem Cell Res Ther
resource representing a document's body	covid:4140dbd5844197838ad213c4b315dfd89e0c0b39#body_text
is schema:about of	named entity 'cesarean' named entity 'scar' named entity 'mesenchymal stem cells' named entity 'safety' named entity 'possibilities' named entity 'obstetricians' named entity 'cesarean' named entity 'singleton' named entity 'frustrated' named entity 'Umbilical cord' named entity 'human tissues' named entity 'cesarean section' named entity 'mesenchymal stem cells' named entity 'stem cells' named entity 'therapeutic strategies' named entity 'biological function' named entity 'confounding' named entity 'ulceration' named entity 'infection' named entity 'clinical studies' named entity 'immunogenicity' named entity 'gestation' named entity 'clinical studies' named entity 'hypopigmented' named entity 'MSCs' named entity 'cesarean delivery' named entity 'metabolic diseases' named entity 'collagen' named entity 'physical examinations' named entity 'spinal cord injury' named entity 'inflammation' named entity 'allergic' named entity 'hyper-pigmentation' named entity 'cesarean section' named entity 'clinical trials' named entity 'hydrogel' named entity 'wound infection' named entity 'Grand Island, NY' named entity 'scar' named entity 'IGF-1' named entity 'Primiparous' named entity 'Epstein-Barr virus' named entity 'Stem cells' named entity 'twin pregnancy' named entity '5.52' named entity 'basic fibroblast growth factor' named entity 'RCT' named entity 'cell culture' named entity 'clinical trials' named entity 'placebo group' named entity 'pregnant women' named entity 'scar' named entity 'vascular endothelial growth factor' named entity 'burn injury' named entity 'adverse effects' named entity 'BUN' named entity 'hepatitis B virus' named entity 'clinical application' named entity 'CD11b' named entity 'cesarean section' named entity 'erythema' named entity 'VSS' named entity 'surgical excision' named entity 'ng/mL' named entity 'placebo group' named entity 'randomly assigned' named entity 'aspartate aminotransferase' named entity 'Randomized clinical trial' named entity 'cell survival' named entity 'adjuvant' named entity 'wound healing' named entity 'MSCs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software